X0609 4 2026-07-23 0 0001853921 Scribe Therapeutics, Inc. SCTX 0001701815 Aghazadeh Behzad false C/O AVORO CAPITAL ADVISORS LLC 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 0 1 See Remarks 0001633313 Avoro Capital Advisors LLC false 110 GREENE STREET SUITE 800 NEW YORK NY 10012 1 0 0 1 See Remarks 0001879253 Avoro Ventures LLC false 110 GREENE STREET, SUITE 800 NEW YORK NY 10012 1 0 0 1 See Remarks 0 Stock Option (Right to Buy) 15 2026-07-23 4 A 0 14725 0 A 2036-07-22 Common Stock 14725 14725 D The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date. This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein. Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer. Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer 2026-07-27 Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer 2026-07-27 /s/ Behzad Aghazadeh 2026-07-27